OBJECTIVES: The aims of this article were: to summarize the pharmacology, pharmacokinetics, and efficacy of daptomycin; to explore its safety profile; and to discuss its current and potential roles as an antimicrobial therapy. METHODS: A literature search was conducted using the MEDLINE (1966-August 2004) and International Pharmaceutical Abstracts (1970-August 2004) databases with the search terms daptomycin, LY146032, and lipopeptide antibiotics. Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy and documents submitted to the US Food and Drug Administration were also reviewed. RESULTS: Phase III study results suggest no difference in efficacy or tolerability between daptomycin 4 mg/kg IV QD and vancomycin or semisynthetic penicillins for complicated skin and skin-structure infections. Animal studies suggest daptomycin may be useful for the treatment of endocarditis. Daptomycin is not indicated for pneumonia, with poorer outcomes than conventional treatment It is available as an IV medication and exhibits 92% plasma protein binding in vitro. In healthy adult humans, daptomycin has a volume of distribution of 0.1 L/kg and a plasma elimination half-life of approximately 9 hours, and is eliminated primarily by renal excretion (approximately 54%). In patients with reduced renal function, including those receiving hemodialysis and peritoneal dialysis, the dose interval should be 48 hours. No dosage adjustment appears to be necessary for mild to moderate hepatic impairment. The use of daptomycin in patients with severe hepatic impairment has not been assessed. The most commonly reported adverse events include constipation, nausea, injection-site reactions, headache, and diarrhea. Patients should also be monitored regularly for skeletal muscle toxicity. CONCLUSIONS: Daptomycin may be useful for complicated skin and skin-structure infections and gram-positive pathogens resistant to conventional antimicrobials. However, limited data are currently available for duration of treatment beyond 14 days and at doses >4 mg/kg QD.
OBJECTIVES: The aims of this article were: to summarize the pharmacology, pharmacokinetics, and efficacy of daptomycin; to explore its safety profile; and to discuss its current and potential roles as an antimicrobial therapy. METHODS: A literature search was conducted using the MEDLINE (1966-August 2004) and International Pharmaceutical Abstracts (1970-August 2004) databases with the search terms daptomycin, LY146032, and lipopeptide antibiotics. Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy and documents submitted to the US Food and Drug Administration were also reviewed. RESULTS: Phase III study results suggest no difference in efficacy or tolerability between daptomycin 4 mg/kg IV QD and vancomycin or semisynthetic penicillins for complicated skin and skin-structure infections. Animal studies suggest daptomycin may be useful for the treatment of endocarditis. Daptomycin is not indicated for pneumonia, with poorer outcomes than conventional treatment It is available as an IV medication and exhibits 92% plasma protein binding in vitro. In healthy adult humans, daptomycin has a volume of distribution of 0.1 L/kg and a plasma elimination half-life of approximately 9 hours, and is eliminated primarily by renal excretion (approximately 54%). In patients with reduced renal function, including those receiving hemodialysis and peritoneal dialysis, the dose interval should be 48 hours. No dosage adjustment appears to be necessary for mild to moderate hepatic impairment. The use of daptomycin in patients with severe hepatic impairment has not been assessed. The most commonly reported adverse events include constipation, nausea, injection-site reactions, headache, and diarrhea. Patients should also be monitored regularly for skeletal muscle toxicity. CONCLUSIONS:Daptomycin may be useful for complicated skin and skin-structure infections and gram-positive pathogens resistant to conventional antimicrobials. However, limited data are currently available for duration of treatment beyond 14 days and at doses >4 mg/kg QD.
Authors: Soju Chang; Dawn M Sievert; Jeffrey C Hageman; Matthew L Boulton; Fred C Tenover; Frances Pouch Downes; Sandip Shah; James T Rudrik; Guy R Pupp; William J Brown; Denise Cardo; Scott K Fridkin Journal: N Engl J Med Date: 2003-04-03 Impact factor: 91.245
Authors: Ian A Critchley; Renée S Blosser-Middleton; Mark E Jones; Clyde Thornsberry; Daniel F Sahm; James A Karlowsky Journal: Antimicrob Agents Chemother Date: 2003-05 Impact factor: 5.191
Authors: Fred C Tenover; Linda M Weigel; Peter C Appelbaum; Linda K McDougal; Jasmine Chaitram; Sigrid McAllister; Nancye Clark; George Killgore; Caroline M O'Hara; Laura Jevitt; Jean B Patel; Bülent Bozdogan Journal: Antimicrob Agents Chemother Date: 2004-01 Impact factor: 5.191
Authors: Véronique Dartois; Jorge Sanchez-Quesada; Edelmira Cabezas; Ellen Chi; Chad Dubbelde; Carrie Dunn; Juan Granja; Colleen Gritzen; Dana Weinberger; M Reza Ghadiri; Thomas R Parr Journal: Antimicrob Agents Chemother Date: 2005-08 Impact factor: 5.191
Authors: Abdalaziz M Awadelkarim; Isra Idris; Muhammad Abdelhai; Ahmed Yeddi; Eltaib Saad; Rashid Alhusain; John Dayco; Mohammed Ali; Lubna Salih Journal: Cureus Date: 2022-06-20
Authors: Leonard T Nguyen; Johnny K Chau; Nicole A Perry; Leonie de Boer; Sebastian A J Zaat; Hans J Vogel Journal: PLoS One Date: 2010-09-10 Impact factor: 3.240
Authors: Terry King-Wing Ma; Chi Bon Leung; Kai Ming Chow; Bonnie Ching-Ha Kwan; Philip Kam-Tao Li; Cheuk Chun Szeto Journal: Clin Kidney J Date: 2016-07-04